Predicting immune-related adverse events in patients with melanoma: the role of interleukin-7 rs16906115 polymorphism and lymphocyte dynamics.

Front Immunol · 2025 · PMC12240767 · PMID 40642097

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.070so close (0.05 < p ≤ 0.1)

Apart from the genotype, an increase in irAE risk was observed in patients treated with the nivolumab–ipilimumab combination, but it did not reach statistical significance (OR 2.139, 95% CI: 0.941–4.86, p = 0.070).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.